Archive for the ‘Slovakia’ Category

Safety Biomarkers in Drug Development

Tuesday, June 16th, 2009

The ability to accurately predict adverse events related to areas like cardiology, nephrology, neurology, haematology and hepatology is extremely exciting. Validated safety biomarkers provide the opportunity for smarter and earlier decision making in R&D, meaning project „kill“ decisions are made quicker, later-stage projects become less risky and hundreds of millions of dollars can be saved.

This conference will summarise what are the most innovative recent scientific developments and the most promising regulatory initiatives, as well as providing a platform for partnering amongst the pharma, biotech, diagnostics and academic sectors.

Why attend?

  • Understand the regulatory requirements to demonstrate safety through biomarkers.
  • Make partnerships and alliances with biomarker R&D experts.
  • Gain access to the latest successful biomarker development case studies.
  • Review multi-stakeholders perspectives: pharma, regulators, research institutes, academia & solution providers.
  • Learn how to integrate biomarker knowledge in monitoring safety in drug development to reduce risk.
  • Identify and understand better, advanced cardiac, renal, hepatological and neurological risk markers.
  • Discover cutting-edge approaches for identification and development of new markers.

Who will benefit:

Pharmaceutical, Biotech, Diagnostic & Academic research organisations:
CEOs / Vice-Presidents / Heads / CSOs / Managers / Professors and Scientists involved in: R&D, drug safety & pharmacovigilance, biomarker discovery/validation, molecular diagnostics, pharmacogenomics/genetics/proteomics, translational medicine, clinical science and development, molecular imaging, pre-clinical development, modeling and simulation, pharmacology, pharmacokinetics/pharmacodynamics

Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Regional Heads

Agenda Request

To request the full agenda please follow the link:

https://www.nextlevelpharma.com/events/request_agenda/safety_biomarkers_in_drug_development

Contact Details:

For Booking Information:

Tel: +421 232 662 621

Fax: +421 232 660 395
Email:
erika@nextlevelpharma.com

Visit: www.nextlevelpharma.com

High-Performance clinical Protocol design and implementation

Tuesday, March 24th, 2009

How important is it for you to plan, design, write and deliver less complex clinical protocols?

NextLevel Pharma is organising a timely meeting which will provide essential perspectives from all stakeholders interested in improving protocol design to maximise clinical objectives without compromising on operational feasibility and simplicity.

Balancing scientific, regulatory & ethical requirements with operational feasibility

( 27th-28th April 2009, Bratislava, Slovakia)
By attending this event you will:

  • Understand the do’s and don’ts in design practicalities.
  • Obtain a clearer view on inconsistent regulations and impediments.
  • Get a global perspective on study delays owning to poor protocol design.
  • Be prepared for evolving regulatory challenges such as risk management measures designed into the protocol at the begining.
  • Learn from expert case studies on how to maximise data benefits from your end points and secondary end points.
  • Enhance your view on scientific colaboration and the pitfalls of poor communication and mutual understanding.

Speakers include:

  • Pfizer, USA- Director Global Outcomes Research
  • Biogen-Idec, USA- Associate Director, Neurology
  • Gilead, UK- Senior Clinical Programme Manager
  • OctoPlus, Netherlands- Chief Medical Officer
  • GenVec, USA- Vice President, Clinical Operations
  • TEVA Pharma, Germany- Director Clinical Research
  • MannKind Corporation, USA- Vice President, Experimental Pharmacology
  • Astellas Pharma Europe- Associate Clinical Research Director
  • European Medical Writers Association, EMWA- President
  • University of East Anglia, UK- Manager Clinical Research and Trials Unit
  • Medical University Vienna, Austria- Professor and Head of Clinical Pharmacology
  • Masaryk Memorial Cancer Institute, Czech Republic
  • University of Tempere Medical School, Finland- Director, Vaccine Research Center
  • Barts and the London Trust, NHS, UK- Research Governance and GCP Manager
  • MDC Partners, Belgium- Partner
  • ACM-Pivotal Global Central Laboratory, UK- Laboratory Director

Together, they will deliver knowledge, expertise, insights, opinions, facts and data that can add strategic intelligence and real-value to your business.

Agenda Request:
To request the agenda, registration form and to learn more about this event, please follow the link:

http://www.nextlevelpharma.com/events/request_agenda/23 
In case you have any problems with link, please contact me directly and I will send the agenda to you immediately.

                                                    

Contact:

Erika Vavrovicova

NextLevel Pharma

ph: +421 2 3266 2621

fax: +421 2 3266 0395

erika@nextlevelpharma.com